You are here: Home: NHLU 2 2005 : CME Information
Non-Hodgkin’s Lymphoma Update:
A CME Audio Series and Activity |
STATEMENT OF NEED/TARGET AUDIENCE
Non-Hodgkin’s lymphoma is increasing in incidence in the United States and is the most commonly occurring
hematologic malignancy. This treatment arena continues to evolve, and published results from ongoing clinical
trials lead to the continuous emergence of new therapeutic agents and changes in the indications for existing
treatments. In order to offer optimal patient care — including the option of clinical trial participation — practicing
hematologists and oncologists must be well informed of these advances. To bridge the gap between research
and patient care, Non-Hodgkin’s Lymphoma Update utilizes one-on-one discussions with leading hematology and
oncology investigators. By providing access to the latest research developments and expert perspectives, this CME
activity assists hematologists and oncologists in the formulation of up-to-date clinical management strategies.
GLOBAL LEARNING OBJECTIVES
- Critically evaluate the clinical implications of emerging clinical trial data in non-Hodgkin’s lymphoma (NHL)
treatment and incorporate these data into management strategies for patients with NHL.
- Counsel appropriately selected patients about the availability of ongoing clinical trials.
- Utilize individual patients’ risk factors and disease classification to tailor therapy for individual subgroups of
patients with NHL.
- Discuss the risks and benefits of monoclonal antibody therapy and radioimmunotherapy alone and in combination
with chemotherapy for patients with NHL, and counsel appropriately selected patients about the risks
and benefits of these agents.
- Describe and implement an algorithm for sequencing of therapies in the management of indolent and
aggressive NHL.
PURPOSE OF THIS ISSUE OF NON-HODGKIN’S LYMPHOMA UPDATE
The purpose of Issue 2 of Non-Hodgkin’s Lymphoma Update is to support these global objectives by offering
the perspectives of Drs Rosen, Smith and Kahl on the integration of emerging clinical research data into the
management of non-Hodgkin’s lymphoma.
ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide
continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Research To Practice designates this educational activity for a maximum of 3 category 1 credits toward the AMA
Physician’s Recognition Award. Each physician should claim only those credits that he/she actually spent in the
activity.
HOW TO USE THIS MONOGRAPH
This CME activity contains both audio and print components. To receive credit, the participant should listen to
the CDs or tapes, review the monograph and complete the post-test and evaluation form located in the back of
this monograph or on our website. This monograph contains edited comments, clinical trial schemas, graphics
and references that supplement the audio program. NHLUpdate.com includes an easy-to-use interactive version
of this monograph with links to relevant full-text articles, abstracts, trial information and other web resources
indicated here in blue underlined text.
|